LFG
RCUS icon

Larson Financial Group’s Arcus Biosciences RCUS Stock Holding History

Larson Financial Group’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$709 Buy
23
+2
+10% +$49 ﹤0.01% 3410
2026
Q1 		$454 Sell
21
-9
-30% -$194 ﹤0.01% 3329
2025
Q4 		$715 Buy
30
+18
+150% +$367 ﹤0.01% 3036
2025
Q3 		$163 Sell
12
-5
-29% -$52 ﹤0.01% 3283
2025
Q2 		$138 Buy
+17
New +$145 ﹤0.01% 3125

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Larson Financial Group's RCUS Position: Q2 2026 in Review

Larson Financial Group increased its Arcus Biosciences (RCUS) stake by 9.5% in Q2 2026, buying an estimated $49 and bringing the position to 23 shares worth $709. The position accounts for ﹤0.01% of the portfolio, ranked #3410.

Larson Financial Group first reported a position in RCUS in Q2 2025 and has held it in 5 quarters since. The position peaked at $715 in Q4 2025. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Larson Financial Group held 23 shares of Arcus Biosciences worth $709 as of Q2 2026.
  • Larson Financial Group bought 2 Arcus Biosciences shares in Q2 2026, an estimated $49.
  • Arcus Biosciences made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #3410 holding.
  • Larson Financial Group first reported a position in Arcus Biosciences in Q2 2025 and has held it in 5 quarters since.
  • Larson Financial Group's Arcus Biosciences position peaked at $715 in Q4 2025.
  • 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.